Any idea which will require more detailed clinicals?
Partly depends on ease of copying which I clearly do not understand the nuances of.
But seems to me that EPO could require clinicals given the recent attention/SEs.
TNF, given toxic side effects, probably would too although the number of similar drugs might argue that any slight variances might not be that important.
Insulin is crucial to life but do the many varied types argue for ease of approval? Many effectively branded generics already in main part of market.
Does the number of beta/alpha interferons and lack of super severe effects argue for easier approval?
Market Data 
Markets 
AI
